Northwest Biotherapeutics (NWBO) Common Equity (2010 - 2026)

Northwest Biotherapeutics' Common Equity history runs 17 years deep, the most recent figure standing at -$50.5 million for Q1 2026.

• In Q1 2026, Common Equity rose 49.19% year-over-year to -$50.5 million; the TTM figure through Mar 2026 stood at -$50.5 million (up 49.19% YoY), while the FY2025 annual figure was -$60.3 million, up 36.2% from the prior year.
• Common Equity for Q1 2026 stood at -$50.5 million, up from -$60.3 million in the prior quarter.
• The five-year high for Common Equity was -$50.5 million in Q1 2026, with the low at -$128.1 million in Q4 2022.
• The 5-year median for Common Equity is -$80.1 million (2024), against an average of -$85.0 million.
• The sharpest annual moves came in 2022 and 2024: Common Equity jumped 73.8% in 2022, then plunged 43.66% in 2024.
• Northwest Biotherapeutics' Common Equity stood at -$128.1 million in 2022, then soared by 48.66% to -$65.8 million in 2023, then tumbled by 43.66% to -$94.5 million in 2024, then soared by 36.2% to -$60.3 million in 2025, then climbed by 16.15% to -$50.5 million in 2026.
• Business Quant data shows NWBO's Common Equity at -$50.5 million in Q1 2026, -$60.3 million in Q4 2025, and -$108.6 million in Q3 2025.